PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM

Inclusion Criteria

• •Adults aged ≥ 60 or aged 50 to 59 with comorbidities (HCT-CI10 score ≥ 3),
• •Hematological malignancies except myeloproliferative syndrome and myelodysplastic syndrome,
• •Patient having received an allograft within ≤ 35 days, performed with the following modalities:
• •* First allogeneic transplant,
• •* Haploidentical donor,
• •* Peripheral stem cell transplant,
• •* Non-myeloablative "Baltimore"-type conditioning, delivered as standard in routine care, as reported in the literature (fludarabine, cyclophosphamide, total body irradiation),
• •* Standard GVHD prophylaxis in the context of haploidentical transplants (post-transplant cyclophosphamide, ciclosporin A and mycophenolate mofetil).
• •Patient discharged from aplasia within ≤ 35 days,
• •Signed informed consent form,
• •Affiliation with a social security.